SCHEMBL3653545

SCHEMBL3653545

Fc1ccc(Oc2ccc(Nc3ccc(F)c(F)c3)nc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 5/20 0.47
SCN5A Q14524 4/20 0.47
KCNH2 Q12809 3/20 0.47
MEN1 O00255 1/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
TTBK1 Q5TCY1 1/20 0.41
TTBK2 Q6IQ55 1/20 0.41
ABL1 P00519 1/20 0.41
LCK P06239 1/20 0.41
ITK Q08881 1/20 0.41
AURKB Q96GD4 1/20 0.41
PRKAA2 P54646 1/20 0.41
CDK8 P49336 2/20 0.40
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
TRPA1 O75762 1/20 0.39
KCNQ1 P51787 1/20 0.39
DHFR P00374 1/20 0.39
MAPK10 P53779 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3657479 0.91 TRPA1 (0.42) SCN9ASCN5ACDK8KCNQ3KCNQ2
SCHEMBL3656271 0.85 EGFR (0.47) SCN9ASCN5AKCNH2MEN1KMT2A
SCHEMBL24867286 0.81 SCN9A (0.55) SCN9ASCN5AKCNH2MEN1ALOX12
SCHEMBL8060597 0.81 GRM5 (0.45) SCN9ASCN5AKCNH2PRKAA2
SCHEMBL3653329 0.80 TGFBR1 (0.46) KCNH2MEN1KMT2A
SCHEMBL3656146 0.80 HDAC6 (0.51) SCN9ASCN5AKCNH2MEN1KMT2A
SCHEMBL1028717 0.79 MEN1 (0.46) MEN1KMT2ADGAT1
SCHEMBL3650073 0.79 APP (0.52) MEN1KMT2ACDK8DHFRDGAT1
SCHEMBL3650602 0.79 MET (0.47) ABL1MAPK10DGAT1
SCHEMBL3648802 0.76 HTT (0.43) KCNH2KMT2AABL1KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
EP-2205317-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES Senexis Limited (GB) 2010-07-14 EP disclosed
WO-2009044160-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2009-04-09 WO disclosed
WO-2009044160-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HCRTR1, HCRTR2, RTN3 SCN9A 53/4885SCN5A 440/4885KCNH2 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.